Mumbai, May 20 -- Profit before tax (PBT) climbed 67.9% YoY to Rs 128.87 crore in Q4 FY25.

During the quarter EBITDA stood at Rs 252 crore, up 70% compared with Rs 148 crore posted in same quarter last year. EBITDA margin expanded to 35.8% in Q4 FY25 as against 26.9% in Q4 FY24.

Revenue from domestic branded formulation (DBF) business jumped 25% YoY to Rs 602 crore in Q4 FY25. The organic base grew 10% to Rs 529 crore, while revenue from Biocon -2 stood at Rs 73 crore during the period under review.

The company reported 22% organic growth in overall insulin revenue to Rs 300 crore despite significant product shortage in RHI throughout the year.

On full year basis, the company's consolidated net profit declined 10.3% to Rs 351.84 crore...